Astatine-211 based radionuclide therapy: Current clinical trial landscape [PDF]
Frontiers in Medicine, 2023 Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT).
Per Albertsson +14 more
doaj +7 more sources
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma [PDF]
Communications Biology, 2022 The efficacy and toxicity of the PARP inhibitor parthanatine, radiolabeled with the alpha particle emitter astatine-211, in 11 patient derived neuroblastoma murine xenografts is investigated.
Mehran Makvandi +22 more
doaj +6 more sources
Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy [PDF]
Journal of Nanobiotechnology, 2021 Background 211At is a high-energy α-ray emitter with a relatively short half-life and a high cytotoxicity for cancer cells. Its dispersion can be imaged using clinical scanners, and it can be produced in cyclotrons without the use of nuclear fuel ...
Hiroki Kato +10 more
doaj +8 more sources
Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates [PDF]
Scientific Reports, 2017 211At is a most promising radionuclide for targeted alpha therapy. However, its limited availability and poorly known basic chemistry hamper its use.
David Teze +7 more
doaj +8 more sources
Astatine-211: production and availability. [PDF]
Curr Radiopharm, 2011 The 7.2-h half life radiohalogen (211)At offers many potential advantages for targeted α-particle therapy; however, its use for this purpose is constrained by its limited availability. Astatine-211 can be produced in reasonable yield from natural bismuth targets via the (209)Bi(α,2n)(211)At nuclear reaction utilizing straightforward methods.
Zalutsky MR, Pruszynski M.
europepmc +6 more sources
Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure. [PDF]
Cancer Biother Radiopharm, 2020 Despite the consensus around the clinical potential of the α-emitting radionuclide astatine-211 (211At), there are only a limited number of research facilities that work with this nuclide. There are three main reasons for this: (1) Scarce availability of the nuclide. Despite a relatively large number of globally existing cyclotrons capable of producing
Lindegren S +5 more
europepmc +5 more sources
Astatine-211 radiolabelling chemistry: from basics to advanced biological applications [PDF]
EJNMMI Radiopharmacy and ChemistryBackground 211At-radiopharmaceuticals are currently the subject of growing studies for targeted alpha therapy of cancers, which leads to the widening of the scope of the targeting vectors, from small molecules to peptides and proteins. This has prompted,
Maarten Vanermen +6 more
doaj +7 more sources
Astatine-211 and actinium-225: two promising nuclides in targeted alpha therapy [PDF]
Acta Biochimica et Biophysica SinicaNuclear medicine therapy offers a promising approach for tumor treatment, as the energy emitted during radionuclide decay causes irreparable damage to tumor cells. Notably, α-decay exhibits an even more significant destructive potential. By conjugating α-
Zuo Dashan +5 more
doaj +4 more sources
cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. [PDF]
PLoS ONE, 2018 The objective of this study was to translate reaction conditions and quality control methods used for production of an astatine-211(211At)-labeled anti-CD45 monoclonal antibody (MAb) conjugate, 211At-BC8-B10, from the laboratory setting to cGMP ...
Yawen Li +15 more
doaj +4 more sources
Development and Utility of an Imaging System for Internal Dosimetry of Astatine-211 in Mice [PDF]
Bioengineering, 2023 In targeted radionuclide therapy, determining the absorbed dose of the ligand distributed to the whole body is vital due to its direct influence on therapeutic and adverse effects. However, many targeted alpha therapy drugs present challenges for in vivo
Atsushi Yagishita +7 more
doaj +2 more sources